Cargando…

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Juliana T. W., Harris, Paul W. R., Brimble, Margaret A., Kavianinia, Iman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510272/ https://www.ncbi.nlm.nih.gov/pubmed/34641391 http://dx.doi.org/10.3390/molecules26195847

Ejemplares similares

Three Decades of Amyloid Beta Synthesis: Challenges and Advances
por: Kasim, Johanes K., et al.
Publicado: (2019)

Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
por: McNamara, Blair, et al.
Publicado: (2023)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Thiol-ene Enabled Chemical Synthesis of Truncated S-Lipidated Teixobactin Analogs
por: Yim, Victor V., et al.
Publicado: (2020)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Novel insights into P450 BM3 interactions with FDA-approved antifungal azole drugs
por: Jeffreys, Laura N., et al.
Publicado: (2019)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
por: Choi, Ha Yeong, et al.
Publicado: (2023)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
por: Krakauer, Teresa
Publicado: (2017)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers
por: Flores Monar, Gabriela Vanessa, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_se7pni173mq14nrqn1oku29r0p